Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

First in class narcolepsy medicine recommended for approval in Europe

The first drug of its kind to treat patients with the rare but long-term sleep disorder narcolepsy is being recommended for use across the European Union (EU).

The European Medicines Agency (EMA) is recommending that pitolisant (Wakix) is granted a marketing authorisation for the treatment of narcolepsy with or without cataplexy — sudden severe muscle weakness or loss of muscle control.

The drug, a first-in-class medicine, is an antagonist of the histamine H3 receptor, leading to an increase in histamine release in the brain, which in turn enhances wakefulness and alertness.

The recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) is based on the results of two placebo-controlled studies involving 259 patients, as well as one uncontrolled, open-label study in 102 patients with narcolepsy and one supportive study in 105 patients.

The studies showed that the drug reduced excessive daytime sleepiness in patients with narcolepsy. Two of the studies revealed benefits for patients who also had cataplexy.

The CHMP has asked the drug manufacturer Bioprojet Pharma to carry out a long-term study in order to further investigate the safety of the medicine, which has had orphan drug status since 2007.

The recommendation, made at the CHMP November 2015 meeting, now has to be approved by the European Commission. It will then be up to individual member states to decide whether to make the drug available within their national health system.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200143

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The European Medicines Agency (EMA), headquarters pictured, is recommending that pitolisant (Wakix) is granted a marketing authorisation for the treatment of narcolepsy with or without cataplexy

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.